The National Medical Commission (NMC) has released the official NEET UG 2026 syllabus, outlining the topics to be covered in ...

Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Background PD-1 blockade has emerged as a promising approach for functional cure of chronic hepatitis B (CHB). Objective This study aimed to evaluate the safety profile of anti-PD-1 antibody (αPD-1), ...

The state Department of Education will develop guidelines for all 600 public school districts to limit the student use of ...

The centerpiece of the Trump administration’s revamp of the U.S. Navy is the largest surface combatant America will build ...

Learn more about whether Legend Biotech Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Findings from the phase 1/2 BRUIN study (NCT03740529) show that pirtobrutinib (Jaypirca), a Bruton tyrosine kinase inhibitor (BTKi), monotherapy offers promising clinical efficacy and a favorable ...

Backed by Sam Altman, this nuclear fission startup has captured the market's imagination, rallying roughly 300% year-to-date on a single premise: AI needs baseload power. Wind and solar are ...

Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive ...

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide for adult ...